SKSteven J. Keteyian

Steven J. Keteyian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Steven J. Keteyian has a total of 140 co-authors. Here are the top co-authors by number of shared publications:

  • Clinton A. Brawner

    Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan

    10 shared publications
  • Jonathan K. Ehrman

    Division of Cardiovascular Medicine, Department of Medicine, Henry Ford Health, Detroit, MI (Dr. Keteyian, Ms. Grimshaw, Dr. Ehrman, Dr. Kerrigan, Mr. Berry, and Dr. Brawner)

    7 shared publications
  • Clinton A. Brawner

    Division of Cardiovascular Medicine, Department of Medicine, Henry Ford Health, Detroit, MI (Dr. Keteyian, Ms. Grimshaw, Dr. Ehrman, Dr. Kerrigan, Mr. Berry, and Dr. Brawner)

    6 shared publications
  • Ileana L. Piña

    Thomas Jefferson University Hospital, Philadelphia, USA

    6 shared publications
  • Dennis J. Kerrigan

    Division of Cardiovascular Medicine, Department of Medicine, Henry Ford Health Detroit, Michigan

    5 shared publications
  • Jerome L. Fleg

    Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland

    5 shared publications

Latest Publications

  • Standing on the Shoulders of Giants …. Indeed

    by Steven J. Keteyian

    Was not provided for this article.

  • The iATTEND Trial: Comparing Hybrid Versus Standard Cardiac Rehabilitation in Patients With Stable Heart Failure

    by Steven J. Keteyian, Crystal Grimshaw, Jonathan K. Ehrman, Dennis Kerrigan, Robert Berry, Clinton A. Brawner

  • Open Access

    Cardiac Rehabilitation Trends Among Commercially Insured Adults in the United States, 2017–2023

    by Lisa M. Pollack, Lyudmyla Kompaniyets, Anping Chang, Michael P. Thompson, Steven J. Keteyian, Haley Stolp, Hilary K. Wall, Laurence S. Sperling, Sandra L. Jackson

    BACKGROUND: Cardiac rehabilitation (CR) reduces morbidity and mortality among individuals with heart disease. Although the COVID-19 pandemic disrupted health services, its impact on CR participation remains poorly understood—especially among commercially insured populations, for whom CR utilization trends are poorly documented. METHODS: This cross-sectional time series study of enrollees aged 18 to 64 years with ≥1 CR-qualifying event (acute myocardial infarction, coronary artery bypass graft, heart valve repair/replacement, percutaneous coronary intervention, or heart/heart-lung transplant) during 2017 to 2022, with follow-up through 2023, used MarketScan commercial claims data. Adjusted analyses used Poisson log-linear models with robust standard errors to examine trends in enrollment and completion (≥36 sessions), and generalized linear models with negative binomial distribution and log-link function to examine trends in days to enrollment and number of sessions. RESULTS: The sample included 143 870 unique individuals aged 18 to 64 years with a CR-qualifying event. Of the sample, the mean age was 53.9 (SD, 8.1), and 70% were men. On average, from 2017 to 2023, enrollment was 24.2%, days to enrollment were 46.3 (SD, 51.4 days), the number of sessions was 13.9 (SD, 12.8), and completion was 9.6%. Compared with year 2017, 2020 was associated with a 12% lower prevalence of enrollment (adjusted prevalence ratio, 0.88 [95% CI, 0.85–0.90]), 6-day longer time to enrollment on average (adjusted difference, 6.04 [95% CI, 4.36–7.72]), 1.2 fewer sessions on average (adjusted difference, −1.24 [95% CI, −1.72 to −0.75]), and 13% lower prevalence of completion (prevalence ratio, 0.87 [95% CI, 0.78–0.97]). All metrics rebounded to prepandemic levels, except days to enrollment (4 days longer in 2022 versus 2017; adjusted difference, 3.78 [95% CI, 2.22–5.34]). CONCLUSIONS: Among commercially insured adults <65 years, only one-quarter of eligible individuals participated in CR. CR metrics worsened during the COVID-19 pandemic in 2020, but most rebounded to prepandemic levels. These findings highlight an opportunity for health systems and public health initiatives to support broader CR uptake.


  • Trends in the Use of Virtual Cardiac Rehabilitation in Medicare, 2019-2021

    by Whitney Md Fu, Hechuan Hou, Donald S. Likosky, Steven J. Keteyian, Chad Ellimoottil, Michael P. Thompson


  • Adherence to Exercise in Adults With Heart Failure

    by Windy W. Alonso, Steven J. Keteyian, Eric S. Leifer, Dalane W. Kitzman, Vandana Sachdev


  • The iATTEND Trial: A Trial Comparing Hybrid Versus Standard Cardiac Rehabilitation

    by Steven J. Keteyian, Crystal Grimshaw, Jonathan K. Ehrman, Dennis J. Kerrigan, Khaled Abdul-Nour, David E. Lanfear, Clinton A. Brawner


  • Open Access

    Heart failure and exercise cardiac rehabilitation in the 21st Century

    by Steven J. Keteyian, Ileana L. Piña

  • Among Patients Taking Beta-Adrenergic Blockade Therapy, Use Measured (Not Predicted) Maximal Heart Rate to Calculate a Target Heart Rate for Cardiac Rehabilitation

    by Steven J. Keteyian, Katherina Steenson, Crystal Grimshaw, Noah Mandel, Wanda Koester-Qualters, Robert Berry, Dennis J. Kerrigan, Jonathon K. Ehrman, Edward L. Peterson, Clinton A. Brawner

    Purpose: Among patients in cardiac rehabilitation (CR) on beta-adrenergic blockade (βB) therapy, this study describes the frequency for which target heart rate (THR) values computed using a predicted maximal heart rate (HRmax), correspond to a THR computed using a measured HRmax in the guideline-based heart rate reserve (HRreserve) method. Methods: Before CR, patients completed a cardiopulmonary exercise test to measure HRmax, with the data used to determine THR via the HRreserve method. Additionally, predicted HRmax was computed for all patients using the 220 − age equation and two disease-specific equations, with the predicted values used to calculate THR via the straight percent and HRreserve methods. The THR was also computed using resting heart rate (HR) +20 and +30 bpm. Results: Mean predicted HRmax using the 220 − age equation (161 ± 11 bpm) and the disease-specific equations (123 ± 9 bpm) differed (P < .001) from measured HRmax (133 ± 21 bpm). Also, THR computed using predicted HRmax resulted in values that were infrequently within the guideline-based HRreserve range calculated using measured HRmax. Specifically, 0 to ≤61% of patients would have had an exercise training HR that fell within the guideline-based range of 50-80% of measured HRreserve. Use of standing resting HR +20 or +30 bpm would have resulted in 100% and 48%, respectively, of patients exercising below 50% of HRreserve. Conclusions: A THR computed using either predicted HRmax or resting HR +20 or +30 bpm seldom results in a prescribed exercise intensity that is consistent with guideline recommendations for patients in CR.


  • Cardiac Rehabilitation and the COVID-19 Pandemic: Persistent Declines in Cardiac Rehabilitation Participation and Access Among US Medicare Beneficiaries

    by Merilyn S. Varghese, Alexis L. Beatty, Yang Song, Jiaman Xu, Laurence S. Sperling, Gregg C. Fonarow, Steven J. Keteyian, Kevin W. McConeghy, Joanne Penko, Robert W. Yeh, et al.

    Background: The impact of the COVID-19 pandemic on participation in and availability of cardiac rehabilitation (CR) is unknown. Methods: Among eligible Medicare fee-for-service beneficiaries, we evaluated, by month, the number of CR sessions attended per 100 000 beneficiaries, individuals eligible to initiate CR, and centers offering in-person CR between January 2019 and December 2021. We compared these outcomes between 2 periods: December 1, 2019 through February 28, 2020 (period 1, before declaration of the pandemic-related national emergency) and October 1, 2021 through December 31, 2021 (period 2, the latest period for which data are currently available). Results: In period 1, Medicare beneficiaries participated in (mean±SD) 895±84 CR sessions per 100 000 beneficiaries each month. After the national emergency was declared, CR participation sharply declined to 56 CR sessions per 100 000 beneficiaries in April 2020. CR participation recovered gradually through December 2021 but remained lower than prepandemic levels (period 2: 698±29 CR sessions per month per 100 000 beneficiaries, P =0.02). Declines in CR participation were most marked among dual Medicare and Medicaid enrollees and patients residing in rural areas or socially vulnerable communities. There was no statistically significant change in CR eligibility between the 2 periods. Compared with 2618±5 CR centers in period 1, there were 2464±7 in period 2 ( P <0.01). Compared with CR centers that survived the pandemic, 220 CR centers that closed were more likely to be affiliated with public hospitals, located in rural areas, and serve the most socially vulnerable communities. Conclusions: The COVID-19 pandemic was associated with a persistent decline in CR participation and the closure of CR centers, which disproportionately affected rural and low-income patients and the most socially vulnerable communities. Innovation in CR financing and delivery is urgently needed to equitably enhance CR participation among Medicare beneficiaries.


  • Heart Failure in Cardiac Rehabilitation

    by Steven J. Keteyian, Alexander Michaels

    Purpose: Exercise cardiac rehabilitation (CR) represents an evidence-based therapy for patients with heart failure with reduced ejection fraction (HFrEF) and this article provides a concise review of the relevant exercise testing and CR literature, including aspects unique to their care. Clinical Considerations: A hallmark feature of HFrEF is exercise intolerance (eg, early-onset fatigue). Drug therapies for HFrEF target neurohormonal pathways to blunt negative remodeling of the cardiac architecture and restore favorable loading conditions. Guideline drug therapy includes β-adrenergic blocking agents; blockade of the renin-angiotensin system; aldosterone antagonism; sodium-glucose cotransport inhibition; and diuretics, as needed. Exercise Testing and Training: Various assessments are used to quantify exercise capacity in patients with HFrEF, including peak oxygen uptake measured during an exercise test and 6-min walk distance. The mechanisms responsible for the exercise intolerance include abnormalities in (a) central transport (chronotropic response, stroke volume) and (b) the diffusion/utilization of oxygen in skeletal muscles. Cardiac rehabilitation improves exercise capacity, intermediate physiologic measures (eg, endothelial function and sympathetic nervous system activity), health-related quality of life (HRQoL), and likely clinical outcomes. The prescription of exercise in patients with HFrEF is generally similar to that for other patients with cardiovascular disease; however, patients having undergone an advanced surgical therapy do present with features that require attention. Summary: Few patients with HFrEF enroll in CR and as such, many miss the derived benefits, including improved exercise capacity, a likely reduction in risk for subsequent clinical events (eg, rehospitalization), improved HRQoL, and adoption of disease management strategies.